CTLA4 and hyperinsulinemic hypoglycemia, familial, 4: evaluated HSCT outcomes in 40 patients with CTLA-4 deficiency, reporting a 3-year overall survival rate of 76.7% and a disease-free survival rate of 74.4% (23).